Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The 12%: Diagnostics “Quick Reviews” Make A Mark, FDA Official Says

This article was originally published in The Gray Sheet

Executive Summary

The first month of the diagnostics office’s “triage” pilot program has led to quicker reviews for some 510(k)s, an agency official reports. To qualify for the program's quick-review pathway, a submission must be of high quality and free of certain time-consuming complexities.

You may also be interested in...



CDRH Dx Office Integrates 30-Day Quick-Reviews Into 510(k) Program

Following a successful 30-day review pilot last fall, CDRH’s diagnostics office started incorporating the quick-review process into its overall 510(k) review program in January. The Office of Device Evaluation is considering following suit.

FDA Claims Short-Term Success For Pre-Market Device Reforms

With many of its 510(k) and science reforms at least partially implemented, CDRH says it is seeing tangible, positive results. The device center cites a turnaround on multiple measures of review performance following the lows of 2010.

Washington Roundup, August 2012

The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we report on recent FDA proposals to streamline the 510(k) and PMA submission processes and the ongoing investigation into FDA surveillance of CDRH employee whistleblowers.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel